*PILOT SCHEME FOR 2025-2026*
Scheme Description
Human Neutrophil Antigens (HNA) are polymorphic glycoproteins found on the surface of neutrophils. These antigens play a crucial role in the immune system. They are important in transplantation and transfusion for several reasons: transfusion reactions such as febrile reactions, transfusion-related acute lung injury (TRALI), transplant rejection and neutropenia. HNA genotyping is used as an aid to investigate and diagnose these clinical conditions.
Purpose
To assess participants’ ability to correctly determine HNA polymorphisms.
Samples
A total of four blood samples will be sent each year as two distributions of two blood samples.
Reporting
Participants can register for assessment for any combination of the following: genotyping at HNA-1,2,3,4 and/or 5.
Participants can report any other HNA polymorphisms they detect for information.
Participants must only use the reporting forms provided within the UK NEQAS for H&I Participant’s Portal and return results within 2 weeks.
Assessment
As this is a pilot scheme, participants will not be formally assessed but will receive a summary of the indicative pilot assessment.
The consensus HNA genotype is determined by at least 75% of laboratories agreeing the presence/absence of each allele. A reference result will be used for assessment for samples failing to reach the 75% consensus level.
Assessment Procedure
Each full HNA genotype in agreement with the consensus/reference genotype – Acceptable
Each full HNA genotype not in agreement with the consensus/reference genotype – Unacceptable
Each sample/registered loci not reported – with valid reason – Not Assessed
Each sample/registered loci not reported / late submission – Unacceptable
Satisfactory Performance
Satisfactory performance is not reported for pilot schemes.
Information/Analysis Provided to Participants
- Anonymised summary table of all participant results, comments and methodology. Including indicative sample assessment result (acceptable/unacceptable classification) for each participant.
